The Pharmacy Times® IVIG Resource Center is a comprehensive resource for clinical news and expert insights on the use of intravenous immunoglobulin, a product comprised of antibodies administered intravenously.
February 22nd 2023
Autoimmune diseases are often chronic conditions that can evolve, so minimizing damage and progression is typically the mainstay of treatment.
IVIG, Steroids for Multisystem Inflammatory Syndrome in Children Have Varying Outcomes
November 16th 2022Despite an apparent benefit of intravenous immunoglobulin (IVIG) on early discharge, the likelihood of needing second-line treatment was 3 times higher in patients who initiated treatment with IVIG alone.
Read More
Effective Treatment for Some Patients with Arndt-Gottron Syndrome Can Be Achieved With IVIG
September 1st 2022Though there is no well-defined therapeutic approach to the treatment of Arndt-Gottron syndrome, intravenous immunoglobulins have been documented as a well-tolerated treatment in some cases.
Read More
Study: Metronidazole Desensitization Effectively Treats Patients with Hypersensitivity Reactions
August 1st 2022Patients with past medical histories of immunoglobulin E-mediated hypersensitivity reactions to metronidazole and other antimicrobial agents may receive safe and effective treatment using desensitization protocols.
Read More
Daily Medication Pearl: Privigen Immune Globulin Intravenous (Human)
July 22nd 2022Privigen is indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.
Read More
Patients with Suspicion of Systemic Disease Require Ongoing Follow-Up for Diagnosis
July 14th 2022A recent case report detailing multiple procedures and inconclusive biopsies underwent by a patient with unusual presentation of immunoglobulin G4-related disease before conclusive diagnosis emphasizes the importance of follow-up with patients with suspicion of systemic disease.
Read More
Investigators Report Series of Substates that Reprogram IgG to 1-Step Synthesis of gsADCs
June 20th 2022Glycosite-specific antibody‒drug conjugates (gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with 2 or more enzymes, which limits the substrate diversification and complicates the preparation process.
Read More
Drug Sequestration in the Management of Patients with Extracorporeal Membrane Oxygenation Support
June 8th 2022Dosing recommendations for patients requiring ECMO support are unlikely to be supported by high-quality evidence, but are usually extrapolated from the physicochemical characteristics of individual drugs in conjunction with data from pharmacokinetic studies and case reports.
Read More